Brief: Sensorion Updates On Progress In Development Of SENS-401 For Prevention Of Hearing Loss

Sensorion SA

05/01/2021 06:44

Jan 5 (Reuters) - Sensorion SA  ALSEN.PA :
    * PROVIDES AN UPDATE ON PLANS AND PROGRESS IN DEVELOPMENT OF SENS-401 FOR
PREVENTION OF HEARING LOSS
    * CLINICAL TRIAL TO TREAT PATIENTS SUFFERING FROM CISPLATIN INDUCED
OTOTOXICITY
(CIO) WITH SENS-401 EXPECTED TO START IN H2 2021
    * ALSO EXPECTS TO START A NATURAL HISTORY CLINICAL STUDY IN CIO IN ADULT
CANCER
PATIENTS IN H1 2021
    * PHASE 2 TOPLINE RESULTS FROM SENS-401 STUDY IN SSNHL DELAYED FURTHER DUE
TO
COVID-19 AND NOW EXPECTED IN Q4 2021
    * SENSORION NOW EXPECTS A FURTHER DELAY IN AVAILABILITY OF TOPLINE RESULTS
FROM
PHASE 2 STUDY OF SENS-401 IN SSNHL
    * TOPLINE DATA ARE NOW ANTICIPATED IN Q4 2021 RATHER THAN MID-2021 AS HAD
BEEN
PREVIOUSLY ESTIMATED
    * CONTINUES TO REVIEW THIS STUDY AND CONSIDER OPPORTUNITIES WHICH COULD AID
IN ITS
SUCCESSFUL COMPLETION DESPITE CHALLENGES PROVIDED BY COVID-19 AND ITS KNOCK-ON
EFFECTS

Source text for Eikon:  ID:nBwbw2GcFa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))